2010
DOI: 10.1128/jvi.01102-10
|View full text |Cite
|
Sign up to set email alerts
|

Potent and Broadly Reactive HIV-2 Neutralizing Antibodies Elicited by a Vaccinia Virus Vector Prime-C2V3C3 Polypeptide Boost Immunization Strategy

Abstract: Human immunodeficiency virus type 2 (HIV-2) infection affects about 1 to 2 million individuals, the majority living in West Africa, Europe, and India. As for HIV-1, new strategies for the prevention of HIV-2 infection are needed. Our aim was to produce new vaccine immunogens that elicit the production of broadly reactive HIV-2 neutralizing antibodies (NAbs). Native and truncated envelope proteins from the reference HIV-2ALI isolate were expressed in vaccinia virus or in bacteria. This source isolate was used d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
39
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 22 publications
(41 citation statements)
references
References 56 publications
2
39
0
Order By: Relevance
“…Specifically, recombinant polypeptides representing the gp125 (rpC2-C3) in infected patients, Marcelino and colleagues did not detect reactive IgG antibodies [50]. Similar results were observed with X4-tropic viruses that were resistant to neutralization in a vaccinia virus vector-prime/rpC2-C3-polypeptideboost vaccination strategy [40]. In the first study, the authors examined nonspecific and Env-specific IgA and IgG responses in acute and chronic HIV-2 infection [50], while in the other work, the same team used a mouse model to investigate the immunogenicity and neutralizing response elicited when a recombinant HIV-2 envelope proteins was administered [40].…”
Section: Discussionsupporting
confidence: 68%
See 4 more Smart Citations
“…Specifically, recombinant polypeptides representing the gp125 (rpC2-C3) in infected patients, Marcelino and colleagues did not detect reactive IgG antibodies [50]. Similar results were observed with X4-tropic viruses that were resistant to neutralization in a vaccinia virus vector-prime/rpC2-C3-polypeptideboost vaccination strategy [40]. In the first study, the authors examined nonspecific and Env-specific IgA and IgG responses in acute and chronic HIV-2 infection [50], while in the other work, the same team used a mouse model to investigate the immunogenicity and neutralizing response elicited when a recombinant HIV-2 envelope proteins was administered [40].…”
Section: Discussionsupporting
confidence: 68%
“…2, Table S1). Coherently, these signatures were already observed in different primary R5 HIV-2 group A isolate [40]. Furthermore, we show the presence of position I320 V3 , which characterizes the R5 cluster with a valine mutation, a signature that is robustly associated with the A378P C3 mutation (P = 8.27e -18 ; u = 0.70, bootstrap = 0.79).…”
Section: Discussionmentioning
confidence: 65%
See 3 more Smart Citations